James Erwin Ml Mcmahon

US Patent:

6673830, Jan 6, 2004

Filed:

Jun 22, 2001

Appl. No.:

09/887375

Inventors:

Michael R. Boyd - Ijamsville MD
Kirk R. Gustafson - Mt. Airy MD
James B. McMahon - Frederick MD
Richard W. Fuller - Tracys Landing MD
Gordon M. Cragg - Bethesda MD
Yoel Kashman - Tel Aviv, IL
Doel Soejarto - Lombard IL

Assignee:

The United States of America as represented by the Secretary of Health and Human Services - Washington DC
The Board of Trustees of the University of Illinois

International Classification:

A01N 4316

US Classification:

514453, 514457, 514460, 549277

Abstract:

The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

US Patent:

6774141, Aug 10, 2004

Filed:

May 20, 1998

Appl. No.:

09/083249

Inventors:

Michael R. Boyd - Ijamsville MD
Kirk R. Gustafson - Mt. Airy MD
James B. McMahon - Frederick MD
Richard W. Fuller - Tracys Landing MD
Gordon M. Cragg - Bethesda MD
Yoel Kashman - Tel Aviv, IL

Assignee:

The United States of America as represented by the Secretary of Health and Human Services - Washington DC

International Classification:

A01N 4316

US Classification:

514453, 514457, 514460, 549247

Abstract:

The present invention provides novel antiviral compounds, refered to as calanolides, related compounds, and their derivatives, which may be isolated from plants, or derived from compounds from plants, of the genus Calophyllum in accordance with the present inventive method. The compounds and their derivatives may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2.

US Patent:

6987096, Jan 17, 2006

Filed:

Nov 13, 1997

Appl. No.:

08/969689

Inventors:

Michael R. Boyd - Ijamsville MD, US
Kirk R. Gustafson - Frederick MD, US
Robert H. Shoemaker - Frederick MD, US
James B. McMahon - Frederick MD, US

Assignee:

The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 31/70

US Classification:

514 44, 424 931, 424 932, 424 9321

Abstract:

The present invention provides antiviral proteins (collectively referred to as cyanovirins), conjugates thereof, DNA sequences encoding such agents, host cells containing such DNA sequences, antibodies directed to such agents, compositions comprising such agents, and methods of obtaining and using such agents.

US Patent:

8470888, Jun 25, 2013

Filed:

Dec 29, 2008

Appl. No.:

12/811144

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Laura K. Cartner - Middletown MD, US
Richard W. Fuller - Fairfield PA, US
Kirk R. Gustafson - Frederick MD, US
Kentaro Takada - Yokohama, JP
James B. McMahon - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human Services - Washington DC

International Classification:

A61K 31/12
C07C 59/86

US Classification:

514679, 562459

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): Formula (I), wherein R, R, R, X, X, X, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.

US Patent:

20100267652, Oct 21, 2010

Filed:

Nov 5, 2008

Appl. No.:

12/742039

Inventors:

Curtis J. Henrich - Rockville MD, US
Heidi R. Bokesch - Frederick MD, US
Susan E. Bates - Bethesda MD, US
Robert W. Robey - Laurel MD, US
Suneet Shukla - Rockville MD, US
Suresh V. Ambudkar - Gaithersburg MD, US
Michael C. Dean - Frederick MD, US
James B. McMahon - Frederick MD, US

International Classification:

A61K 31/7042
A61K 31/4985
A61K 31/519
A61K 31/4439
A61K 31/40
A61K 31/295
A61P 35/04

US Classification:

514 26, 514250, 5142621, 514341, 514418, 514501

Abstract:

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.

US Patent:

20110190240, Aug 4, 2011

Filed:

Sep 22, 2009

Appl. No.:

13/120044

Inventors:

Curtis J. Henrich - Rockville MD, US
Moon-Il Kang - Gyeongsangnam-do, KR
Heidi R. Bokesch - Frederick MD, US
Kirk R. Gustafson - Frederick MD, US
Nancy H. Colburn - Middletown MD, US
Matthew R. Young - Ijamsville MD, US
James B. McMahon - Frederick MD, US

Assignee:

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES - Bethesda MD

International Classification:

A61K 31/655
A61P 35/00
A61P 3/10
A61P 35/02
A61P 29/00
A61P 13/08
A61P 1/18
A61P 1/04
A61P 11/06
C12Q 1/02

US Classification:

514150, 435 29

Abstract:

An embodiment of the invention provides a pharmaceutical composition comprising a compound of formula (I)a pharmaceutically acceptable salt, prodrug, hydrate, or solvate thereof. Another embodiment of the invention provides a method of treating or preventing a condition associated with increased expression and/or activity of an NFκB pathway using same compounds. A further embodiment of the invention provides a method of diagnosing a condition in an individual using same compounds.

US Patent:

55998399, Feb 4, 1997

Filed:

Apr 17, 1995

Appl. No.:

8/424558

Inventors:

Michael R. Boyd - Ijamsville MD
Paul A. Cox - Provo UT
Gordon M. Cragg - Bethesda MD
Peter M. Blumberg - Frederick MD
Nancy A. Sharkey - Rockville MD
Junichi Ishitoya - Bethesda MD
James B. McMahon - Frederick MD
John A. Beutler - Braddock Heights MD
Owen S. Weislow - Reston VA
John H. Cardellina - Walkersville MD
Krik R. Gustafson - Wheaton MD

Assignee:

The United States of America as represented by the Department of Health
and Human Services - Washington DC
Brigham Young University - Provo UT

International Classification:

A61K 3122

US Classification:

514546

Abstract:

The present invention relates to an antiviral composition and to methods of treating patients with viral infections. The antiviral composition of the present invention comprises prostratin, a phorbol ester derivative, and a pharmaceutically acceptable carrier. The present composition while having antiviral activity does not have substantial tumor promoting activity and does not have other substantial adverse toxicological properties that would preclude its use in antiviral therapy.

US Patent:

58695222, Feb 9, 1999

Filed:

May 31, 1995

Appl. No.:

8/455679

Inventors:

Michael R. Boyd - Ijamsville MD
Kirk R. Gustafson - Mt. Airy MD
Laurent A. Decosterd - Nyon, CH
Ian Parsons - Ithaca NY
Lewis Pannell - Silver Spring MD
James B. McMahon - Frederick MD
Gordon M. Cragg - Bethesda MD

Assignee:

The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC

International Classification:

A01N 4316
C07C 5004
C07D31102
C07D31104

US Classification:

514456

Abstract:

The present invention provides novel antiviral naphthoquinone compounds, which may be isolated from plants of the genus Conospermum or synthesized chemically, in accordance with the present inventive methods. The antiviral naphthoquionone compounds, derivatives thereof, and prodrugs thereof, may be used alone or in combination with other antiviral agents in compositions, such as pharmaceutical compositions, to inhibit the growth or replication of a virus, such as a retrovirus, in particular a human immunodeficiency virus, specifically HIV-1 or HIV-2, in the treatment or prevention of viral infection.